• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude launches Prodigy spinal cord stimulator in Canada

St. Jude launches Prodigy spinal cord stimulator in Canada

May 20, 2015 By Fink Densford

St. Jude launches Prodigy spinal cord stimulator in Canada

St. Jude Medical (NYSE:STJ) said today that it won Health Canada approval for its Prodigy spinal cord stimulator for treating chronic pain.

The 1st Canadian Prodigy implantation was performed May 13 by Dr. Ivar Mendez of the University of Saskatchewan, St. Jude said.

The Prodigy device is designed to deliver low levels of electricity to nerve fibers in the spinal cord to interrupt or mask pain signals as they travel to the brain, St. Jude said. The device also uses St. Jude’s proprietary "burst stimulation" that the company claims reduces or eliminates paresthesia.

"Burst stimulation is a novel technology for SCS that has the potential to be effective in patients that do not respond well to traditional tonic stimulation. Studies have shown that with Burst stimulation patients can experience reduced paresthesia and pay less attention to their pain improving their overall experience with SCS therapy. SCS therapy can provide significant pain relief and thus enable many patients to increase their activity levels and improve their overall quality of life. In combination with conventional tonic stimulation, Burst stimulation represents a comprehensive approach to effective pain management and allows me to tailor the therapy to my patient’s unique situation," Mendez said in prepared remarks.

St. Jude won CE Mark approval in the European Union for its Prodigy device in March 2014, and launched a 442-patient clinical trial in late 2013 under an investigational device exemption in the U.S., seeking a chronic pain indication from the FDA.

Earlier this month the FDA granted pre-market approval to the Senza chronic pain device made by Nevro Corp. (NYSE:NVRO), which is also designed to eliminate paresthesia.

Filed Under: Neuromodulation/Neurostimulation, News Well, Pain Management, Regulatory/Compliance, Spine Tagged With: Health Canada, stjudemedical

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy